Medical Imaging Management Leader M2S Names Ciaran Cooper General Manager of Clinical Trials Services Division
M2S Inc., an industry leader in medical image management and analysis, announced today that it has named Ciaran Cooper its new General Manager of Clinical Trials Services. Cooper was previously Vice President of Clinical Trials Services at M2S, which he joined in March 2007. Before joining M2S, Cooper was with Beacon Bioscience (now ICON Medical Imaging) an imaging core lab servicing the pharmaceutical industry.
(PRWEB) April 30, 2008 -- M2S Inc. (www.m2s.com), an industry leader in medical image management and analysis, announced today that it has named Ciaran Cooper its new General Manager of Clinical Trials Services.
General Manager of Clinical Trials Services
Mr. Cooper was previously Vice President of Clinical Trials Services at M2S, which he joined in March 2007. Before joining M2S, Mr. Cooper was with Beacon Bioscience (now ICON Medical Imaging) an imaging core lab servicing the pharmaceutical industry. Mr. Cooper has 20 years experience in the medical imaging industry with 13 years spent in clinical trials imaging services, including senior sales and marketing roles and general operations management. Mr. Cooper was the founding President and CEO of MIICRO, Inc. (now Abiant Imaging) where he helped pioneer the use of PET imaging in Central Nervous System (CNS) drug development. Mr. Cooper was also President and CEO of Insight Sciences LLC, a provider of specialized remote image reading systems.
In his new role at M2S, Mr. Cooper will be responsible for daily operations of the rapidly expanding Clinical Trials Services division, as well as integration of key technologies and the development and implementation of strategic partnerships and acquisitions.
"Ciaran brings the right mix of proven management experience, leadership skills, and entrepreneurial zeal to our organization," said M2S's CEO Wes Chapman. "His industry knowledge and vision for helping our clients develop new therapeutics and medical devices through the strategic use of medical imaging technologies complement beautifully our best-in-class capabilities and 15 year history of excellence. We look forward to his leadership and continued contributions to our growing business in this key market."
About M2S
M2S (www.m2s.com) is a pioneer in image management services and technology, and is a recognized innovator in imaging core lab services for clinical trials. For the past 15 years, the company has worked with many of the world's leading academic centers, pharmaceutical companies, and medical device manufacturers, managing, under protocol, millions of images from around the globe. M2S develops image-based systems and protocols that reduce time, cost, and uncertainty in clinical trials for the pharmaceutical, biotech, and medical device industries.
M2S's proprietary DICOM ArmorCar® (DAC®) image transfer technology has revolutionized the way medical images are transported between sites, core labs, and clinical trial sponsors. The DAC transfers image data securely in their original digital DICOM format for immediate, real-time QC assessment and query generation/resolution. In addition to its preservation of data integrity, the DAC provides unmatched time savings and eliminates the immense costs associated with storing data on CDs and shipping them via courier - a standard practice in the industry today. The DAC is the first system designed specifically to address these significant issues, and the expansion of its global integration will allow clinical trial sponsors to utilize its power to manage their large international trials more efficiently and cost-effectively than ever before. DACs have already been installed and implemented in over 250 institutions in the U.S., with additional sites in in Europe, South America, and Asia.
###
Post Comment: Trackback URL: http://www.prweb.com/pingpr.php/U3F1YS1TcXVhLU1hZ24tSG9yci1GYWx1LVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.